Royal DSM N.V.
Q3 2011 Results

Life Sciences and Materials Sciences

Presentation to Investors

HEALTH · NUTRITION · MATERIALS

DSM
BRIGHT SCIENCE. BRIGHTER LIVING.

DSM – Bright Science. Brighter Living.™

Royal DSM N.V. is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, pharmaceuticals, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM's 22,000 employees deliver annual net sales of around € 9 billion. The company is listed on NYSE Euronext. More information can be found at www.dsm.com.

DSM
BRIGHT SCIENCE. BRIGHTER LIVING.

DSM in motion: *driving focused growth*

Q3 results 2011

HEALTH · NUTRITION · MATERIALS

Overview

- **Operational performance Q3 2011**
- Progress on strategy
- Outlook

DSM
BRIGHT SCIENCE. BRIGHTER LIVING.

Highlights Q3 2011

DSM reports strong Q3 results

- Q3 EBITDA from continuing operations €339 million, 26% ahead of Q3 2010
- Organic sales growth 14%
- Robust performance in Life Sciences despite significant impact of Swiss franc
- Very good Materials Sciences results driven by Polymer Intermediates
- Martek continued its excellent performance; integration completed
- DSM Sinochem Pharmaceuticals joint venture established
- EPS (before exceptional items, continuing operations) up 38% to €0.94
- Outlook confirmed: 2011 expected to be a strong year

Quote Feike Sijbesma

- *“We are pleased to have delivered continued profitable growth compared to last year across all business clusters. This performance has been achieved despite the significant impact of a very strong Swiss franc and a weak US dollar.”*
- *“Our outlook remains unchanged: 2011 is expected to be a strong year with further progress towards achieving our 2013 targets. However, DSM remains vigilant to possible negative developments in the global economy. Through Q3 we have experienced weakening in the electronics and electrical markets and in the depressed building and construction markets. DSM would not be immune to a deterioration in the economic environment, however, we have transformed DSM into a much more balanced and stronger company with a relatively resilient portfolio in health, nutrition and materials, a broad geographic spread with a strong presence in high growth economies and a solid balance sheet.”*



Feike Sijbesma
Chairman of the Managing Board

DSM
BRIGHT SCIENCE. BRIGHTER LIVING.

Results Q3 2011 - Key figures

Q3-2011	Q3-2010	Δ%	(€ million)	YTD-2011	YTD-2010	Δ%
			Continuing operations before exceptional items:			
2,322	2,041	+14%	Net Sales	6,821	6,049	+12%
339	268*	+26%**	EBITDA	1,003	885*	+13%**
231	169*	+37%	EBIT	700	582*	+20%
0.94	0.68	+38%	EPS (€)	2.82	2.26	+ 25%
			Total DSM before exceptional items:			
2,322	2,212	+5%	Net Sales	6,966	6,848	+2%
339	292	+16%	EBITDA	1,032	988	+4%
			Total DSM including exceptional items:			
171	79	+116%	Net profit	729	358	+104%
1.00	0.46	+117%	EPS (€)	4.33	2.14	+102%

* of which €7 million (Jan-Sep €24 million) IFRS pension adjustment
**30% (Jan-Sep 16%) if IFRS pension adjustment is excluded

DSM
BRIGHT SCIENCE. BRIGHTER LIVING.

EBITDA - DSM continuing business

EBITDA (€ million)	YTD-2011	YTD-2010	YTD-2009 (*)	YTD-2008 (*)
Nutrition	542	521	481	396
Pharma	25	35	57	105
Performance Materials	250	227	122	275
Polymer Intermediates	301	156	18	105
Innovation Center (*)	-40	-36	(**)	(**)
Corporate Activities (*)	-75	-18	-104	-75
DSM core business	1,003	885	574	806

* 2008 & 2009 not restated for changes in pension accounting and corporate research costs
** 2008 & 2009 Innovation Center was reported in Corporate activities

Net sales growth Q3 2011 versus Q3 2010

(€ million)	Q3 2011	Q3 2010	Diff.	Volume	Price	FX	Other
Nutrition	868	751	16%	8%	0%	-2%	10%
Pharma	171	168	2%	13%	1%	-4%	-8%
Performance Materials	711	666	7%	-4%	11%	-3%	3%
Polymer Intermediates	473	340	39%	19%	26%	-6%	
Innovation Center	15	17					
Corporate Activities	84	99					
Continuing Operations	2,322	2,041	14%	6%	8%	-3%	3%(*)

* Including the effect of the deconsolidation of Sitech Manufacturing Services which was reported in Corporate activities in 2010

DSM
BRIGHT SCIENCE. BRIGHTER LIVING.

Nutrition

Q3-2011	Q3-2010	Δ%	(€ million)	YTD-2011	YTD-2010	Δ%
868	751	+16%	Net Sales	2,505	2,247	+11%
176	167	+5%	EBITDA	542	521	+4%
134	133	+1%	EBIT	428	419	+2%
20.3%	22.2%		EBITDA margin	21.6%	23.2%	

- Sales increased by 16% reflecting steady organic sales growth of 8%, especially in Animal Nutrition & Health, and the Martek acquisition.
- Performance continued to be robust with 5% EBITDA improvement versus last year. Volume growth, Martek and cost optimization efforts more than offset headwinds from currencies (around € 25m), raw material costs and energy costs.
- Martek delivered an excellent performance with sales of €84m and EBITDA of €26m. The integration of Martek has been successfully completed.

DSM
BRIGHT SCIENCE. BRIGHTER LIVING.

Pharma

Q3-2011	Q3-2010	Δ%	(€ million)	YTD-2011	YTD-2010	Δ%
171	168	+2%	Net Sales	512	549	-7%
13	7	+86%	EBITDA	25	35	-29%
3	-7		EBIT	-7	-8	
7.6%	4.2%		EBITDA margin	4.9%	6.4%	

- Organic sales growth was 14%, mainly driven by higher volumes from DSM Pharmaceutical Products.
- EBITDA improved compared to 2010 level but is still well below acceptable level.
- The 50/50 JV DSM Sinochem Pharmaceuticals was established and has been proportionally consolidated as of September, impacting reported figures.

Performance Materials

Q3-2011	Q3-2010	Δ%	(€ million)	YTD-2011	YTD-2010	Δ%
711	666	+7%	Net Sales	2,125	1,867	+14%
77	72	+7%	EBITDA	250	227	+10%
47	43	+9%	EBIT	162	136	+19%
10.8%	10.8%		EBITDA margin	11.8%	12.2%	

- Organic sales growth was 7%, mainly due to strong pricing at DSM Engineering Plastics and DSM Resins. Unit margins continued to improve.
- Higher volumes at DSM Engineering Plastics versus last year, but lower volumes at DSM Resins due to further weakening in building & construction and lower volumes in the tender driven vehicle protection business of DSM Dyneema.
- Higher EBITDA compared to Q3 2010 fully attributable to DSM Engineering Plastics.

DSM
BRIGHT SCIENCE. BRIGHTER LIVING.

Polymer Intermediates

Q3-2011	Q3-2010	Δ%	(€ million)	YTD-2011	YTD-2010	Δ%
473	340	+39%	Net Sales	1,353	1,016	+33%
109	46	+137%	EBITDA	301	156	+93%
96	38	+153%	EBIT	272	132	+106%
23.0%	13.5%		EBITDA margin	22.2%	15.4%	

- Ongoing high global utilization rate resulting in excellent pricing, 26% above last year.
- Volumes higher versus last year due to yield improvements and Q3 2010 maintenance shutdown in China.
- Continued pricing strength and higher margins, combined with higher volumes and excellent manufacturing performance, drove results to record high EBITDA.

DSM
BRIGHT SCIENCE. BRIGHTER LIVING.

Innovation Center

Q3-2011	Q3-2010	Δ%	(€ million)	YTD-2011	YTD-2010	Δ%
15	17	-12%	Net Sales	43	35	+23%
-14	-10		EBITDA	-40	-36	
-16	-13		EBIT	-48	-44	
-	-		EBITDA margin	-	-	

- Lower EBITDA due to lower sales and costs related to the Actamax® JV with DuPont in DSM Biomedical and increased innovation costs for new projects at DSM Bio-based Products & Services.
- Acquisition of C5 Yeast Company B.V. from Royal Cosun completed, increasing leadership position in 2nd generation biofuels.
- In addition to cellulosic biofuels, DSM invests in developing bio-succinic acid, biogas, biodiesel and bio-adipic acid businesses.
- DSM Personalized Nutrition was sold.

DSM
BRIGHT SCIENCE. BRIGHTER LIVING.

Cash flow

Cash Flow (€ million)	YTD '11	YTD '10
Cash from operating activities	479	690
Cash from investing activities	-229	-7
Free cash flow from operations	250	683

Balance sheet (€ million)	Ult. Q3 2011	YE 2010
Net debt	304	-108
Gearing	5%	-2%



DSM
BRIGHT SCIENCE. BRIGHTER LIVING.

Overview

- Operational performance Q3 2011
- Progress on strategy
- Outlook

BRIGHT SCIENCE. BRIGHTER LIVING.

Global societal trends drive DSM's markets



BRIGHT SCIENCE. BRIGHTER LIVING.

DSM in motion: *driving focused growth*



Share Life Sciences increased from 43% to 59%





Excluding discontinued and corporate activities

DSM
BRIGHT SCIENCE. BRIGHTER LIVING.

Sales growth through four growth drivers

High Growth Economies from 32% to 50%



Innovation from 12% to 20%



ECO+ % of running business on track



Growth via acquisitions and partnerships

Acquisitions	Partnerships
Martek	Sinochem
Vitadene	Sinopec
Microbia	KuibyshevAzot
Premix Facilities	Kemrock
Shandong ICD	EBAs (DuPont, Roquette)
AGI	
C5 Yeast Company	

DSM
BRIGHT SCIENCE. BRIGHTER LIVING.

Increasing profitability towards 2013 targets



DSM BRIGHT SCIENCE. BRIGHTER LIVING.

More solid financial base





Stable and preferably rising dividend

- Dividend policy: "stable and preferably rising dividend"
- DSM kept dividend unchanged during 2008/2009 downturn
- April 2011:
  - Increase dividend by 12.5% to €1.35
  - Introduce optional stock dividend
- Further dividend increase to at least €1.50 in coming years

Dividend per ordinary share (€)



DSM
BRIGHT SCIENCE. BRIGHTER LIVING.

Nutrition: continued value growth

	Aspiration by 2015	YTD 2011
•	Growth GDP + 2%	4%
•	EBITDA margin >20 - 23%	22%

Strategy progress

- Improvement in operations/processing
- Successful innovations introduced
- Expansion of premix and strengthened franchise stores
- Expanded offering through M&A:
  - Martek (PUFAs)
  - Microbia/Vitatene (Natural Carotenoids)
  - New premix plants

Growth in ingredients & infrastructure



Active Ingredients → Delivery Systems (& Forms) → Premix & Blends

DSM BRIGHT SCIENCE. BRIGHTER LIVING.

Pharma: Leveraging partnerships for growth

	Aspiration by 2015	YTD 2011
•	EBITDA margin >15% towards 20%	5%

Strategy progress

- JV with Sinochem established (50% participation for € 210m)
- 6-APA plant under construction
- Partnership discussions for DPP in progress
- Biopharma plant under construction funded by Australian Government

DSM Sinochem Pharmaceuticals established

- 6-APA plant complete 2012
- 5 new products launched
- 1st success in FD and dossiers
- Ongoing debottlenecking

DPP partnership in progress

- Pipeline in progress
- Cost restructuring ongoing
- Fast growing bio-pharma

DSM BRIGHT SCIENCE. BRIGHTER LIVING.

PM: Growing via innovative sustainable solutions

	Aspiration by 2015	YTD 2011
•	Growth at 2 x GDP	13%
•	EBITDA margin >17%	12%

Strategy progress

- Strong sales growth, but slowing down
  - Focus on High Growth Economies
  - Launches of sustainable innovations
  - Weakening growth in B&C and E&E
- Active margin and cost management
- Selective acquisitions & partnerships
  - UV coatings in Taiwan
  - High performance fibers China
  - Engineering plastics in Russia
  - Composite resins partnerships in China and India

Sales and EBITDA growth (€ m)



DSM
BRIGHT SCIENCE. BRIGHTER LIVING.

PI: Strengthening backward integration for DEP

Aspiration by 2015	YTD 2011
• EBITDA margin ~ 14% (on average over the cycle)	22%

Strategy progress

- Strengthened backward integration for DSM Engineering Plastics
  - Partnership KuibyshevAzot Russia
- Strengthened global leadership position
  - China 2nd line 2014; 200kt (~30% additional capacity) Lowest carbon footprint in China
  - US lower variable costs
  - Europe improved production reliability/performance

GUR Caprolactam



DSM BRIGHT SCIENCE. BRIGHTER LIVING.

EBAs: Building new growth platforms

- Continued strong growth (>15% pa)
- Cardiovascular, Orthopedic & Ophthalmic as main markets focus
- Strong pipeline of new developments, several development agreements signed
- Actamax®, a DSM JV with DuPont, started its activities
- Value capturing through
  - broadening of the portfolio
  - expansion in the value chain
  - royalties from licenses
  - selective acquisitions

- DSM well positioned for cellulosic bio-fuels
  - no. 1 position in yeasts
  - top 3 position in enzymes
- Acquisition of C5 Yeast Company B.V. from Royal Cosun, increasing leadership position in cellulosic biofuels
- DSM and Roquette have announced a commercial scale bio-based succinic acid plant
- Other growth platforms in development: biogas, biodiesel, bio-based adipic acid

Strategic highlights since CMD 29-9-2011

- Acquisitions completed
  - Majority share in Shangdong ICD High Performance Fiber Co. in China
  - Fatrom Furajeri Additivi, the leading premix player in Rumania

- DSM Resins to optimize and streamline global organization and accelerate switch to highly innovative and sustainable business
  - Results negatively affected by ongoing weakness in building & construction markets
  - Close few smaller operations (reduce ~90 fte)
  - Reduce global staff (~210 fte)
  - Annualized costs savings ~€ 25-30m in 2013

DSM
BRIGHT SCIENCE. BRIGHTER LIVING.

On track towards achieving ambitious targets

Profitability targets 2013		YTD 2011
EBITDA	€ 1.4 - 1.6bn*	€ 1.0bn
ROCE	>15%	>15% incl Martek

Sales targets 2015		YTD 2011
Organic sales growth	5% - 7% annually	13%
China sales	from US$ 1.5bn to >US$ 3bn	US$ 1.5bn
High Growth Economies	from ~32% towards 50% of total sales	38%
Innovation	from ~12% to 20% of total sales	18%

EBA aspiration 2020		YTD 2011
EBA sales	>€ 1bn	Good progress (esp. BP&S, Biomedical)

* 2010 EBITDA was € 1,127m (IFRS pension adjustment is excluded)

Nutrition and PM expected to drive profit growth



* 2010 EBITDA was € 1,127m (IFRS pension adjustment is excluded)

Confident about achieving ROCE >15%



2013: EBIT increase > +25-50%



2013: Capital Employed > +10-15%

- ROCE 2010 continued operations 14.6%
- Expected ROCE 2013 excl. acquisitions clearly above 15%
- Considerable organic improvement leaves room for acquisitions

DSM BRIGHT SCIENCE. BRIGHTER LIVING.

Currency exposure and EBITDA sensitivity

Net sales exposure:
- US Dollar 1.6bn
- Japanese Yen 10bn

Net cost exposure:
- Swiss Franc 800m
- Pound Sterling 150m

Majority of currency exposure in Nutrition:

~ 60% of US Dollar

~ 80% of Japanese Yen

~100% of Pound Sterling and Swiss Franc





DSM BRIGHT SCIENCE. BRIGHTER LIVING.

Hedging the currency exposure

- Policy: foreign currency hedging of 50% of the net transaction exposure of USD, JPY and GBP
- No hedging of translation exposure
- Rolling hedge strategy



Achievements

- Hedging result u/i Q3 2011 € 53.5m
- Replaced ARO US$ 112m to CHF (US$/CHF 0.74) by ARF (US$/CHF 0.84) in September

DSM
BRIGHT SCIENCE. BRIGHTER LIVING.

Overview

- Operational performance Q3 2011
- Progress on strategy
- **Outlook**

BRIGHT SCIENCE. BRIGHTER LIVING.

Current business trading in DSM end-markets

End-market demand

• Food	good
• Feed	strong
• CMO Pharma	moderate
• Automotive /Transport	good
• E&E	good*
• Building & Construction	weak*
• Packaging	good
• Textile	good

Geographic demand

• EU, US	moderate*
• Asia, Latam	strong*

Net sales 2010 by end-market



* Weakening compared to the previous quarters

DSM BRIGHT SCIENCE. BRIGHTER LIVING.

Outlook confirmed

- Assuming no major changes to the overall business conditions
- Nutrition results including Martek are expected to be clearly above last year
- Pharma results are expected to be lower than in 2010
- Performance Materials results are expected to be above last year
- Polymer Intermediates full year results are expected to be excellent
- 2011 will be a strong year;
  with further progress towards achieving the 2013 targets

Disclaimer

- This document may contain forward-looking statements with respect to DSM's future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company.
- Examples of forward-looking statements include statements made or implied about the company's strategy, estimates of sales growth, financial results, cost savings and future developments in its existing business as well as the impact of future acquisitions, and the company's financial position. These statements can be management estimates based on information provided by specialized agencies or advisors.
- DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause the company's actual performance and position to differ materially from these statements.
- These factors include, but are not limited to, macro-economic, market and business trends and conditions, (low-cost) competition, legal claims, the ability to protect intellectual property, changes in legislation, changes in exchange and interest rates, changes in tax rates, pension costs, raw material and energy prices, employee costs, the implementation of the company's strategy, the company's ability to identify and complete acquisitions and to successfully integrate acquired companies, the company's ability to realize planned disposals, savings, restructuring or benefits, the company's ability to identify, develop and successfully commercialize new products, markets or technologies, economic and/or political changes and other developments in countries and markets in which DSM operates.
- As a result, DSM's actual future performance, position and/or financial results may differ materially from the plans, goals and expectations set forth in such forward-looking statements.
- DSM has no obligation to update the statements contained in this document, unless required by law. The English language version of this document is leading.
- A more comprehensive discussion of the risk factors affecting DSM's business can be found in the company's latest Annual Report, a copy of which can be found on the company's corporate website, www.dsm.com

Contact:

BRIGHT SCIENCE. BRIGHTER LIVING.

DSM Investor Relations
P.O. Box 6500, 6401 JH Heerlen, The Netherlands
☎ (+31) 45 578 2864
e-mail: investor.relations@dsm.com
internet: www.dsm.com

visiting address: Het Overloon 1, Heerlen, The Netherlands

HEALTH · NUTRITION · MATERIALS

DSM
BRIGHT SCIENCE. BRIGHTER LIVING.

Press Release

Heerlen (NL), 1 November 2011

DSM, Corporate Communications
email media.relations@dsm.com
www.dsm.com

70E

DSM reports strong Q3 results

Q3 EBITDA from continuing operations €339 million, 26% ahead of Q3 2010
Organic sales growth 14%
Robust performance in Life Sciences despite significant impact of Swiss franc
Very good Materials Sciences results driven by Polymer Intermediates
Martek continued its excellent performance; integration completed
DSM Sinochem Pharmaceuticals joint venture established
EPS (before exceptional items, continuing operations) up 38% to €0.94
Outlook confirmed: 2011 expected to be a strong year

Commenting on the results, Feike Sijbesma, CEO/Chairman of the DSM Managing Board, said:
"We are pleased to have delivered continued profitable growth compared to last year across all business clusters. This performance has been achieved despite the significant impact of a very strong Swiss franc and a weak US dollar.

"Our outlook remains unchanged: 2011 is expected to be a strong year with further progress towards achieving our 2013 targets. However, DSM remains vigilant to possible negative developments in the global economy. Through Q3 we have experienced weakening in the electronics and electrical markets and in the depressed building and construction markets. DSM would not be immune to a deterioration in the economic environment, however, we have transformed DSM into a much more balanced and stronger company with a relatively resilient portfolio in health, nutrition and materials, a broad geographic spread with a strong presence in high growth economies and a solid balance sheet."

third quarter 2011	third quarter 2010	+/-	*in € million*	January - September 2011	January - September 2010	+/-
			Continuing operations:			
2,322	**2,041**	***14%***	Net sales	**6,821**	**6,094**	***12%***
			Operating profit before depreciation			
339	**268***	***26%****	and amortization (EBITDA)	**1,003**	**885***	***13%****
176	167		- Nutrition	542	521	
13	7		- Pharma	25	35	
77	72		- Performance Materials	250	227	
109	46		- Polymer Intermediates	301	156	
-14	-10		- Innovation Center	-40	-36	
-22	-14		- Corporate activities	-75	-18*	
			* of which €7 million (January - September €24 million) IFRS pension adjustment			
			** 30% (January - September 16%) if IFRS pension adjustment is excluded			
231	169*	*37%*	Operating profit (EBIT)	700	582*	*20%*
			Discontinued operations:			
-	171		Net sales	145	754	
			Operating profit before depreciation			
-	24		and amortization (EBITDA)	29	103	
-	19		Operating profit (EBIT)	29	76	
			Total DSM:			
2,322	**2,212**	***5%***	Net sales	**6,966**	**6,848**	***2%***
			Operating profit before depreciation			
339	292	*16%*	and amortization (EBITDA)	1,032	988	*4%*
159	**128**	***24%***	Net profit before exceptional items	**497**	**430**	***16%***
12	-49		Net result from exceptional items	232	-72	
171	**79**	***116%***	Net profit	**729**	**358**	***104%***
			Net earnings per ordinary share in €:			
			- before exceptional items, continuing			
0.94	0.68	*38%*	operations	2.82	2.26	*25%*
			- including exceptional items,			
1.00	0.46	*117%*	total DSM	4.33	2.14	*102%*

In this report:

'operating profit' (before depreciation and amortization) is understood to be operating profit (before depreciation and amortization) before exceptional items;

'net profit' is the net profit attributable to equity holders of Royal DSM N.V.;

'continuing operations' refers to the DSM operations excluding DSM Agro, DSM Melamine, DSM Special Products B.V., S.A. Citrique Belge N.V and DSM Elastomers;

'discontinued operations' comprise net sales and operating profit (before depreciation and amortization) of DSM Agro and DSM Melamine up to and including Q2 2010, S.A. Citrique Belge N.V. up to and including Q3 2010, DSM Special Products B.V. up to and including Q4 2010 and DSM Elastomers up to and including Q2 2011.

Overview of third quarter 2011
The monetary and financial instability continued to increase during Q3 with substantial currency volatility. The Swiss franc in particular appreciated very strongly, reaching an all time high and almost parity against the euro in Q3 before stabilizing at a lower, but still very high level. On average, the Swiss franc was 13% stronger against the euro compared to Q3 last year. The US dollar was 10% weaker compared to Q3 2010.

The governmental austerity programs combined with the financial turmoil and a drop in consumer and producer confidence caused a slowdown in economic growth in the developed world. The building and construction sector continues to be weak, and demand has also weakened in the electronics and electrical markets. In the high growth economies, economic growth slowed marginally, partly due to interventions to address inflationary pressure.

DSM believes that it is well positioned to face the challenges caused by this difficult macro-economic environment. The Life Sciences clusters are relatively resilient to the economic turmoil and DSM overall is benefiting from its strong presence in high growth economies, especially China.

Net sales	**third quarter**					
in € million	2011	2010	differ-ence	organic growth	exch. rates	other
Nutrition	868	751	16%	8%	-2%	10%
Pharma	171	168	2%	14%	-4%	-8%
Performance Materials	711	666	7%	7%	-3%	3%
Polymer Intermediates	473	340	39%	45%	-6%	
Innovation Center	15	17				
Corporate activities	84	99				
Total (continuing operations)	2,322	2,041	14%	14%	-3%	3%*
Discontinued operations		171				
Total	2,322	2,212				

* Including the effect of the deconsolidation of Sitech Manufacturing Services, which was reported in Corporate activities in 2010.

Q3 was the seventh consecutive quarter with double digit organic sales growth (14%), of which 6% from volumes and 8% from prices. Prices increased mainly in Materials Sciences, which resulted in a further improvement of margins. The volume trend in most businesses remained very sound. As in Q2, DSM Dyneema was affected by lower sales to the tender driven vehicle protection business.

Net sales in China (continuing operations in USD) increased by 52% from USD 364 million in Q3 2010 to USD 554 million in Q3 2011. Total sales in high growth economies increased to 40% of overall DSM sales in Q3 2011.

Total EBITDA in Q3 was €339 million, which is 26% higher than last year and equal to Q2 2011. All business clusters posted a better result than in Q3 2010.

Nutrition continued to deliver year-on-year profit growth despite the strength of the Swiss franc. Martek once again delivered an excellent performance that clearly exceeded expectations.

The Pharma results continued to improve, mainly due to DSM Pharmaceutical Products.

In Performance Materials DSM Engineering Plastics more than compensated for the drop in results at DSM Dyneema.

Polymer Intermediates posted its best quarter ever, driven by extremely good margins and an excellent manufacturing performance.

Business review by cluster

Nutrition

third quarter		*in € million*	January - September	
2011	2010		2011	2010
868	751	Net sales	2,505	2,247
176	167	EBITDA	542	521
134	133	EBIT	428	419
20.3%	22.2%	EBITDA margin	21.6%	23.2%

Sales in Q3 2011 increased by 16% over the same period last year due to a steady organic sales growth of 8%, reflecting the strong volumes in Animal Nutrition & Health, and the Martek acquisition. Overall prices were in line with Q3 last year. The currency impact on sales of -2% was mainly caused by the weak US dollar. Compared to the second quarter of this year, organic sales growth was 1%, as a result of improving prices.

The performance of the cluster continued to be robust with **EBITDA** margins above 20%. EBITDA in Q3 improved compared to last year despite the negative impact of currencies (of around €25 million net of hedging results, mainly Swiss franc related) and higher raw material and energy costs. These negative effects were compensated for by volume growth, the effect of the Martek acquisition and the ongoing efforts to optimize costs.

Martek delivered an excellent performance with sales of €84 million and EBITDA of €26 million. The integration of Martek has been successfully completed.

Pharma

third quarter		*in € million*	January - September	
2011	2010		2011	2010
171	168	Net sales	512	549
13	7	EBITDA	25	35
3	-7	EBIT	-7	-8
7.6%	4.2%	EBITDA margin	4.9%	6.4%

Organic **sales** growth was 14%, mainly driven by higher volumes from DSM Pharmaceutical Products, which were partially offset by lower volumes from DSM Sinochem Pharmaceuticals.

Higher sales volumes drove an increase in **EBITDA** in Q3 compared to last year. However, EBITDA was still well below an acceptable level.

The anti-infectives joint venture between DSM and Sinochem Group was established in the third quarter. DSM has proportionally consolidated the joint venture, DSM Sinochem Pharmaceuticals, at 50% as of 1 September 2011. This impacted the reported net sales (-8%) and EBITDA of the cluster.

Performance Materials

third quarter		*in € million*	January - September	
2011	2010		2011	2010
711	666	Net sales	2,125	1,867
77	72	EBITDA	250	227
47	43	EBIT	162	136
10.8%	10.8%	EBITDA margin	11.8%	12.2%

The Performance Materials cluster delivered 7% organic **sales** growth, mainly due to strong pricing at DSM Engineering Plastics and DSM Resins. Volumes were higher at DSM Engineering Plastics because of its improved market position. Volumes at DSM Resins were lower due to further weakening in the building & construction markets. Volumes at DSM Dyneema were lower as growth in fiber solutions and personal protection was more than offset by lower volumes in the tender driven vehicle protection business.

Prices and unit margins continued to improve at DSM Engineering Plastics and DSM Resins compared to last year. **EBITDA** for the cluster improved slightly compared to Q3 2010 as a consequence of higher results at DSM Engineering Plastics, partly offset by lower results at DSM Dyneema, which are mainly related to lower volumes in the vehicle protection business.

Polymer Intermediates

third quarter		*in € million*	January - September	
2011	2010		2011	2010
473	340	Net sales	1,353	1,016
109	46	EBITDA	301	156
96	38	EBIT	272	132
23.0%	13.5%	EBITDA margin	22.2%	15.4%

Polymer Intermediates achieved organic **sales** growth of 45% compared to Q3 2010. The cluster continued to benefit from the high global utilization rate, resulting in excellent pricing. Prices were 26% above last year's level. Volumes were higher in comparison to last year due to yield improvements in operations in both caprolactam and acrylonitrile and a maintenance shutdown in China in Q3 2010.

Polymer Intermediates continued to show a substantial **EBITDA** increase compared to the same period last year. Continued pricing strength and higher margins, combined with higher sales volumes and an excellent manufacturing performance, drove the result to a new record high.

Innovation Center

third quarter		*in € million*	January - September	
2011	2010		2011	2010
15	17	Net sales	43	35
-14	-10	EBITDA	-40	-36
-16	-13	EBIT	-48	-44

EBITDA was lower than Q3 2010 due to lower sales and costs related to the Actamax® Joint Venture with DuPont in DSM Biomedical and increased innovation costs for the new projects in DSM Bio-based Products & Services.

The C5 Yeast Company BV acquisition was completed on 28 July, through which DSM will further increase its leadership position in the field of second generation biofuels. In addition to cellulosic biofuels DSM invests in developing bio-succinic acid, biogas, biodiesel and bio-adipic acid businesses. DSM Personalized Nutrition was sold to Viocare, Inc. on 13 September. DSM will remain involved in the business as a minority shareholder in Viocare through DSM Venturing.

Corporate activities

third quarter		*in € million*	January - September	
2011	2010		2011	2010
84	99	Net sales	283	380
-22	-14	EBITDA*	-75	-18
-33	-25	EBIT*	-107	-53
	7	* of which IFRS pension adjustment		24

The lower EBITDA in Q3 2011 compared to Q3 2010 was mainly due to the changes in the Dutch pension plan. These lower results were partly compensated for by lower share based payment costs in line with the development of the share price during Q3.

Exceptional items
Total *exceptional items* in Q3 2011 amounted to €12 million profit after tax, comprising an after tax book profit of € 39 million in relation to the establishment of the DSM Sinochem Pharmaceuticals joint venture, an after tax book loss of €16 million for non-recurring value adjustments of inventories in relation to the Martek acquisition and an after tax loss of €11 million in relation to DSM Resins' restructurings.

Net profit
Net profit increased from €79 million in Q3 2010 to €171 million in Q3 2011, which was mainly due to the strong increase in operating profit, a lower tax rate and the net result of exceptional items.

Net finance costs amounted to €15 million in Q3 2011 compared to €16 million in Q3 2010.

The effective tax rate was 21% (Q3 2010 25%). The lower tax rate was a result of a different geographical spread of results and the application of preferential tax regimes. The decrease was negatively impacted by the very strong results in Polymer Intermediates, which were partly realized in high tax jurisdictions.

Net earnings per ordinary share (continuing operations, excluding exceptional items) increased by 38% to a level of €0.94 per ordinary share in Q3 2011 (Q3 2010: €0.68).

Cash flow, capital expenditure and financing
Cash provided by operating activities in Q3 was €323 million, bringing the year-to-date total to €479 million.

Operating working capital increased from 21.0% of sales at the end of Q2 2011 to 21.6% of sales at the end of Q3 2011.

Cash flow related to *capital expenditure* amounted to -€144 million in Q3 2011, which is an increase compared to prior quarters, due to several large projects entering the construction phase. Year-to-date capital expenditure was €304 million (€251 million in 2010). Cash flow from *acquisitions* amounted to -€58 million in Q3, mainly related to AGI Corporation of Taiwan and C5 Yeast Company.

Net debt increased during the quarter from €278 million to €304 million.

Progress of strategy: DSM in motion: *driving focused growth*
DSM in motion: *driving focused growth* marks the shift from an era of intensive portfolio transformation to a strategy for the coming years of maximizing sustainable and profitable growth of 'the new DSM'. The current businesses compose the new core of DSM in Life Sciences and Materials Sciences. Below is an update on DSM's achievements and progress in the third quarter of 2011.

DSM established the 50/50 global joint venture for its business group DSM Anti-Infectives with Sinochem Group. The joint venture includes all of the current DSM Anti-Infectives activities across the world. DSM Sinochem Pharmaceuticals aims to increase its sales to more than €600 million with an EBITDA margin above 15% by 2015.

DSM successfully completed the acquisition of a majority share of 91.75% in Shandong ICD High Performance Fibre Co. Ltd. (ICD) in China. ICD is a manufacturer of UHMWPE (ultra high molecular weight polyethylene) fiber and a strong player in the high-performance fiber market in China. The acquisition brings complementary manufacturing and technology assets to DSM and substantially strengthens the company's presence in this key market.

DSM also finalized the acquisition of a 51% stake in AGI Corporation of Taiwan (AGI), producer of a broad range of environmentally friendly UV (ultraviolet) curable resins and other products. The acquisition is one of the initiatives from DSM Resins to strengthen its market position in high growth economies and high-end sustainable, innovative products. On 28 July a fire occurred at the Shinhua site of AGI in Taiwan. As a result, 7 employees were injured. DSM deeply regrets this serious accident.

The building and construction markets in Europe and the US continue to be depressed and this is negatively affecting DSM Resins' results. In order to achieve its objectives, including accelerating its switch to highly innovative and sustainable business (styrene free resins, powder-, waterborne and UV resins), the business group will optimize and streamline its global organization. Therefore, DSM Resins will close a few smaller operations in the United Kingdom and Taiwan (90 fte) and reduce its global staff (210 fte, of which 130 fte in the Netherlands). For this purpose an exceptional item of approximately €26 million (after tax) will be recorded in 2011, of which €11 million (after tax) in Q3. These actions are expected to result in annualized cost savings of €25-30 million in 2013.

In Romania DSM completed the acquisition of the premix unit of Fatrom Furajeri Additivi, the country's leading premix manufacturer. It allows DSM to expand its global network of premix facilities and offers improved access to the growing Romanian livestock feed market.

DSM once again retained its number one position in the chemical industry sector in the Dow Jones Sustainability World Index. This is the third consecutive year that DSM has held this top position in worldwide sustainability and the sixth time in total since 2004. In 2007 and 2008, the two years when DSM was not ranked number one, it was still among the leaders in the sector.

Outlook 2011

The outlook for the remainder of the year is consistent with DSM's earlier expectations. However, DSM is mindful of the impact that a deterioration in macro-economic conditions could have on its end markets. At the same time DSM remains confident that it will continue to benefit from its balanced, relatively resilient portfolio in health, nutrition and materials, its broad geographic spread with a strong presence in high growth economies, and its solid balance sheet.

DSM assumes that there will be no major changes to the overall business conditions for the remainder of the year.

The Nutrition cluster is expected to maintain its resilient performance through firm pricing and continued volume growth. At the current exchange rate the Swiss franc is estimated to have a negative impact of between €10 million and €15 million net of hedges in Q4 2011 compared to last year. Including Martek, full year EBITDA for the cluster is expected to be clearly above last year's level.

Conditions in the Pharma cluster remain challenging and the overall results are anticipated to be lower than in 2010. DSM has proportionally consolidated DSM Sinochem Pharmaceuticals at 50% as of 1 September 2011.

In Performance Materials, unit margins have clearly increased during the year. However, the cluster will continue to be impacted by weakening demand in building and construction and electronics and electrical and lower sales at DSM Dyneema related to the tender driven vehicle protection business as previously communicated. The cluster is expected to report full year results above last year.

The Polymer Intermediates business continues to benefit from very strong, although softening trading conditions. Polymer Intermediates' full year results are expected to be excellent.

DSM remains confident that 2011 will be a strong year with further progress being made towards achieving the EBITDA target of €1.4 billion to 1.6 billion in 2013, in conjunction with a ROCE of more than 15%.

Additional information

Today DSM will hold a conference call for the media from 08.00 AM to 08.30 AM CET and a conference call for investors and analysts from 09.00 AM to 10.00 AM CET. Details on how to access these calls can be found on the DSM website, www.dsm.com. Also, information regarding DSM's Q3 2011 results can be found in the Presentation to Investors, which can be downloaded from the Investors section of the DSM website.

Condensed consolidated statement of income for the third quarter

third quarter 2011			*in € million*	third quarter 2010		
before exceptional items	exceptional Items	total		before exceptional items	exceptional Items	total
2,322		2,322	net sales	2,212		2,212
339	47	386	EBITDA from continuing operations	268	-4	264
			EBITDA from discontinued operations	24	1	25
339	47	386	EBITDA total DSM	292	-3	289
231	-21	210	operating profit (EBIT)	188	-53	135
			operating profit from discontinued operations	19	-37	-18
231	-21	210	operating profit from continuing operations	169	-16	153
-15		-15	net finance costs	-16		-16
2		2	share of the profit of associates	4		4
218	-21	197	profit before income tax expense	157	-16	141
-46	33	-13	income tax expense	-40	5	-35
172	12	184	net profit from continuing operations	117	-11	106
			net profit from discontinued operations	14	-38	-24
172	12	184	profit for the period	131	-49	82
-13		-13	non-controlling interests	-3		-3
159	12	171	net profit	128	-49	79
159	12	171	net profit	128	-49	79
-3		-3	dividend on cumulative preference shares	-2		-2
156	12	168	net profit used for calculating earnings per share	126	-49	77
108	68	176	depreciation and amortization	104	50	154
		136	capital expenditure			91
		106	acquisitions			12
			net earnings per ordinary share in €			
0.94	0.06	1.00	- net earnings, total DSM	0.76	-0.30	0.46
0.94	0.06	1.00	- net earnings, continuing operations	0.68	-0.06	0.62
		166.4	average number of ordinary shares (x million)			164.1
		165.4	number of ordinary shares, end of period (x million)			164.6
		21,702	workforce (headcount) at end of period			*21,911
		6,146	of which in the Netherlands			*6,754

* Year-end 2010

This report has not been audited.

Condensed consolidated statement of income for January - September

January - September 2011			*in € million*	January - September 2010		
before exceptional items	exceptional Items	total		before exceptional items	exceptional Items	total
6,966		6,966	net sales	6,848		6,848
1,003	30	1,033	EBITDA from continuing operations	885	6	891
29	110	139	EBITDA from discontinued operations	103	-31	72
1,032	140	1,172	EBITDA total DSM	988	-25	963
729	72	801	operating profit (EBIT)	658	-82	576
29	110	139	operating profit from discontinued operations	76	-76	0
700	-38	662	operating profit from continuing operations	582	-6	576
-54	140	86	net finance costs	-66		-66
5		5	share of the profit of associates	4		4
651	102	753	profit before income tax expense	520	-6	514
-137	19	-118	income tax expense	-131	2	-129
514	121	635	net profit from continuing operations	389	-4	385
21	111	132	net profit from discontinued operations	53	-68	-15
535	232	767	profit for the period	442	-72	370
-38		-38	non-controlling interests	-12		-12
497	232	729	net profit	430	-72	358
497	232	729	net profit	430	-72	358
-8		-8	dividend on cumulative preference shares	-7		-7
489	232	721	net profit used for calculating earnings per share	423	-72	351
303	68	371	depreciation and amortization	330	57	387
		290	capital expenditure			257
		907	acquisitions			46
			net earnings per ordinary share in €			
2.94	1.39	4.33	- net earnings, total DSM	2.58	-0.44	2.14
2.82	0.71	3.53	- net earnings, continuing operations	2.26	-0.02	2.24
		166.2	average number of ordinary shares (x million)			163.7
		165.4	number of ordinary shares, end of period (x million)			164.6
		21,702	workforce (headcount) at end of period			*21,911
		6,146	of which in the Netherlands			*6,754

* Year-end 2010

This report has not been audited.

Consolidated balance sheet: assets*

in € million	30 September 2011		year-end 2010	
intangible assets	1,698		1,070	
property, plant and equipment	3,148		2,943	
deferred tax assets	285		326	
associates	58		25	
other financial assets	140		271	
	--------		--------	
non-current assets		**5,329**		**4,635**
inventories	1,644		1,340	
trade receivables	1,652		1,361	
other receivables	206		116	
financial derivatives	46		134	
current investments	633		837	
cash and cash equivalents	1,539		1,453	
	--------		--------	
		5,720		5,241
assets to be contributed to joint ventures				317
assets held for sale		48		287
		--------		--------
current assets		**5,768**		**5,845**
		--------		--------
total assets		**11,097**		**10,480**

* For information on the impact of the consolidation of Martek and DSM Sinochem Pharmaceuticals on the consolidated balance sheet please refer to the Notes to the financial statements on page 17 to 19.

DSM
BRIGHT SCIENCE. BRIGHTER LIVING.

Consolidated balance sheet: equity and liabilities*

in € million	30 September 2011		year-end 2010	
shareholders' equity	5,746		5,481	
non-controlling interests	168		96	
	--------		--------	
equity		**5,914**		**5,577**
deferred tax liabilities	228		155	
employee benefits liabilities	270		297	
provisions	100		93	
borrowings	2,018		1,992	
other non-current liabilities	63		33	
	--------		--------	
non-current liabilities		**2,679**		**2,570**
employee benefits liabilities	20		24	
provisions	44		33	
borrowings	181		105	
financial derivatives	323		219	
trade payables	1,333		1,277	
other current liabilities	589		512	
	--------		--------	
		2,490		2,170
liabilities to be contributed to joint ventures				104
liabilities held for sale		14		59
		---------		--------
current liabilities		**2,504**		**2,333**
		---------		--------
total equity and liabilities		**11,097**		**10,480**
capital employed **		6,463		5,468
equity / total assets**		53%		53%
net debt**		304		-108
gearing (net debt / equity plus net debt)**		5%		-2%
operating working capital, continuing operations		1,984		1,487
OWC / net sales, continuing operations		21.6%		17.9%

***** For information on the impact of the consolidation of Martek and DSM Sinochem Pharmaceuticals on the consolidated balance sheet please refer to the Notes to the financial statements on page 17 to19.

****** Before reclassification to Held for sale

Condensed consolidated cash flow statement

in € million		January - September 2011		2010
cash, cash equivalents and current investments at beginning of period		2,290		1,347
current investments at beginning of period		-837		-7
cash and cash equivalents at beginning of period		1,453		1,340
operating activities:				
- EBITDA	1,172		963	
- change in working capital	-472		-160	
- interest and income tax	-55		-86	
- other	-166		-27	
cash provided by operating activities		479		690
investing activities:				
- capital expenditure	-304		-251	
- acquisitions	-858		-63	
- disposal of subsidiaries and businesses	502		350	
- disposal of other non-current assets	222		11	
- change in fixed-term deposits	210		-50	
- other	-1		-4	
cash used in investing activities		-229		-7
dividend	-153		-206	
repurchase of shares	-278			
other cash from financing activities	171		17	
cash used in financing activities		-260		-189
changes in consolidation and exchange differences		96		50
cash and cash equivalents at end of period		1,539		1,884
current investments at end of period		633		57
cash, cash equivalents and current investments at end of period		2,172		1,941

Condensed consolidated statement of comprehensive income

in € million	January - September 2011	2010
exchange differences on translation of foreign operations	-40	191
actuarial gains and losses and asset ceiling*		-8
other changes	-159	37
income tax expense	38	14
other comprehensive income	-161	234
profit for the period	767	370
total comprehensive income	606	604

* With the introduction of the defined contribution plan in 2011 for DSM in the Netherlands €765 million has been transferred from the reserve for actuarial gains & losses to the other retained earnings.

Condensed consolidated statement of changes in equity

in € million	January - September 2011	2010
total equity at beginning of period	5,577	5,011
changes:		
- total comprehensive income	606	604
- dividend	-242	-206
- repurchase of shares	-278	
- proceeds from reissue of ordinary shares	199	38
- other changes	52	23
total equity at end of period	5,914	5,470

Condensed report business segments

January - September 2011 *(in € million)*

	Continuing operations								Discon-tinued operations	Elimina-tion	Total
	Nutrition	Pharma	Perform-ance Materials	Polymer Interme-diates	Innovation Center	Corporate activities	Elimina-tion	Total continuing operations			
net sales	2,505	512	2,125	1,353	43	283		6,821	145		6,966
supplies to other clusters	53	19	14	339	3	18	-445	1	6	-7	
total supplies	2,558	531	2,139	1,692	46	301	-445	6,822	151	-7	6,966
EBITDA	542	25	250	301	-40	-75		1,003	29		1,032
EBIT	428	-7	162	272	-48	-107		700	29		729
total assets	5,219	1,405	2,555	1,193	407	10,929	-10,611	11,097			11,097
workforce (headcount) at end of period	8,149	3,222	5,417	1,410	363	3,141		21,702			21,702

January - September 2010 *(in € million)*

	Continuing operations								Discon-tinued operations	Elimina-tion	Total
	Nutrition	Pharma	Perform-ance Materials	Polymer Interme-diates	Innovation Center	Corporate activities	Elimina-tion	Total continuing operations			
net sales	2,247	549	1,867	1,016	35	380		6,094	754		6,848
supplies to other clusters	37	11	35	304	3	13	-356	47	92	-139	
total supplies	2,284	560	1,902	1,320	38	393	-356	6,141	846	-139	6,848
EBITDA	521	35	227	156	-36	-18		885	103		988
EBIT	419	-8	136	132	-44	-53		582	76		658
total assets*	4,648	1,367	2,794	966	443	9,894	-9,632	10,480			10,480
workforce (headcount) at end of period*	7,409	4,079	4,918	1,361	309	3,417		21,493	418		21,911

*Year-end 2010

Geographical information (continuing operations)

January - September 2011

	The Netherlands	Rest of Western Europe	Eastern Europe	North America	Latin America	China	India	Japan	Rest of Asia	Rest of the World	Eliminations	Total
net sales by origin												
in € million	2,444	1,917	61	1,157	181	726	86	92	123	34		6,821
in %	36	28	1	17	3	11	1	1	2			100
net sales by destination												
in € million	502	2,085	380	1,265	429	1,067	120	221	600	152		6,821
in %	7	30	6	19	6	16	2	3	9	2		100
total assets in € million	11,246	7,062	94	2,528	460	1,260	92	163	306	51	-12,165	11,097
workforce (headcount)												
at end of period	6,146	6,388	320	3,615	764	3,000	465	142	726	136		21,702

January - September 2010

	The Netherlands	Rest of Western Europe	Eastern Europe	North America	Latin America	China	India	Japan	Rest of Asia	Rest of the World	Eliminations	Total
net sales by origin												
in € million	2,212	1,877	48	919	173	565	90	71	107	32		6,094
in %	36	31	1	15	3	9	1	1	2	1		100
net sales by destination												
in € million	403	1,924	318	1,180	435	832	118	189	551	144		6,094
in %	7	32	5	19	7	14	2	3	9	2		100
workforce (headcount)												
at end of period*	6,491	6,381	241	2,878	979	3,170	662	139	400	152	-	21,493

*Year-end 2010

Notes to the financial statements

- Accounting policies and presentation

The consolidated financial statements of DSM for the year ended 31 December 2010 were prepared according to International Financial Reporting Standards (IFRS) as adopted by the European Union and valid as of the balance sheet date. The same accounting policies are applied in the current interim financial statements, as of 30 September 2011. These statements are in compliance with IAS 34 'Interim Financial Reporting' and need to be read in conjunction with the Integrated Annual Report 2010 and the discussion by the Managing Board earlier in this interim report. Neither pensions and similar obligations nor plan assets are subjected to interim revaluation. From the first quarter of 2011 onwards, the Dutch pension plan is reported as a defined contribution plan. The presentation of business segments and the geographical information has been aligned with the new strategy DSM in motion: *driving focused growth*.

- Audit

These interim financial statements have not been audited.

- Scope of the consolidation

On 25 February 2011 DSM obtained control of Martek BioSciences Corporation (Martek). From that date onwards the financial statements of Martek are consolidated by DSM and reported in the Nutrition segment. Martek has annual sales of approximately USD 450 million and employs about 600 people. In accordance with IFRS 3 the purchase price of Martek needs to be allocated to identifiable assets and liabilities acquired. This so-called purchase price allocation is currently ongoing. The provisional results of the purchase price allocation were reported in the interim report for the first quarter of 2011 and are presented below.

The impact of the acquisition of Martek on DSM's consolidated balance sheet, at the date of acquisition, is shown in the following table. This information is based on the provisional results of the purchase price allocation and may change when more final information becomes available.

Acquisition of Martek *in € million*		Fair value
intangible assets	254	
property, plant and equipment	134	
other non-current assets	11	
inventories	87	
receivables	55	
cash and cash equivalents	58	
total assets		599
non-current liabilities	93	
current liabilities	47	
total liabilities		140
net assets at fair value		459
acquisition price (in cash)	789	
acquisition price (payable)	5	
total consideration		794
goodwill		335

On 12 July 2011 DSM obtained control of AGI Corporation of Taiwan (AGI) through the acquisition of a 51% stake in the company for €41 million. From that date onwards the financial statements of AGI are consolidated by DSM and reported in the Performance Materials segment. AGI has annual sales of approximately TWD 4 billion (€100 million) and employs about 300 people. In accordance with IFRS 3 the purchase price of AGI needs to be allocated to identifiable assets and liabilities acquired. In this report the provisional results of the purchase price allocation are used which may change when more final information becomes available.

On 28 July 2011 DSM obtained control of C5 Yeast Company BV. From that date onwards the company is consolidated by DSM and reported in the Innovation Center. In accordance with IFRS 3 the purchase price of C5 Yeast Company BV needs to be allocated to identifiable assets and liabilities acquired. In this report the provisional results of the purchase price allocation are used which may change when more final information becomes available.

Both acquisitions were immaterial with respect to other disclosure requirements of IFRS 3.

In the second quarter of 2011 DSM completed the sale of DSM Elastomers (Keltan®) to LANXESS for €338 million on a cash and debt-free basis. In view of the disposal the related activities are reported as discontinued operations and comparatives have been re-presented. The impact of the deconsolidation of these activities is presented in the table below:

Sale of DSM Elastomers (Keltan®) *in € million*		
intangible assets and property, plant and equipment	132	
other non-current assets	5	
inventories	84	
receivables	50	
cash and cash equivalents	40	
total assets		311
non-controlling interests	-5	
non-current liabilities	2	
current liabilities	37	
total liabilities		34
net asset value		277
total consideration, net of selling costs, translation differences, taxes and net debt		388
book profit (after income tax expense)		111

The impact of the disposal on the cash flow statement is presented in the following table:

in € million	January-April 2011	Full year 2010
net cash provided by operating activities	-14	60
net cash used in investing activities	-3	-8
net cash from/used in financing activities	0	0
net change in cash and cash equivalents	-17	52

Before disposal the business was classified as asset/liabilities held for sale and discontinued operations.

In the third quarter of 2011 DSM completed the formation of the DSM Sinochem Pharmaceuticals joint venture which is consolidated on a 50% proportionate basis from 1 September 2011 onwards. As a consequence of the transaction 50% of the assets and liabilities of the business were effectively sold to the joint venture partner. DSM continues to account for the assets and liabilities that are retained in the business on the basis of existing book values. In view of DSM's continuing involvement with the business the related activities remain part of continuing operations. The impact of the 50% disposal is presented in the table below:

Sale of 50% of DSM Anti-infectives *in € million*		
intangible assets and property, plant and equipment	72	
other non-current assets	17	
inventories	41	
receivables	67	
cash and cash equivalents	17	
total assets		214
non-controlling interests	4	
non-current liabilities	26	
current liabilities	92	
total liabilities		122
net asset value		92
total consideration, net of selling costs, value adjustments and taxes		131
book profit (after income tax expense)		39

Before disposal the business was classified as asset/liabilities to be contributed to joint ventures.

In view of the expected disposal of the Maleic Anhydride and Derivatives business of DSM Pharmaceutical Products in Linz (Austria) in 2011, this business was classified as 'assets/liabilities held for sale' at the end of 2010. For these assets depreciation and amortization was stopped upon reclassification.

- Related party transactions

Transactions with related parties are conducted at arm's length conditions.

- Risks

DSM has a risk management system in place. A description of the system and an overview of potentially important risks for DSM are provided in the Integrated Annual Report 2010 and in the governance section on www.dsm.com. DSM has reviewed the developments and incidents in the first half of 2011 and assessed the risks for the rest of the year at the time of issuance of the Half-year report 2011. On the basis of that assessment DSM concluded that the most important risks and responses as reported in the Integrated Annual Report 2010 were still applicable.

- Seasonality

In cases where businesses are significantly affected by seasonal or cyclical fluctuations in sales this is discussed in the 'Business review by cluster' earlier in this report.

- Dividends and equity

On 25 May the final dividend of €0.95 per share for the year 2010 was paid to holders of ordinary shares and a dividend of €0.15 per share was paid to holders of cumulative preference shares A. The total distribution to shareholders amounting to €164 million, of which €61 million was paid as stock dividend, was recorded against retained earnings. In addition to the final dividend for 2010 the interim dividend of €0.45 per ordinary share for 2011 was recognized in the second quarter of 2011. This distribution to shareholders amounted to €78 million, of which €29 million paid as stock dividend, and was recorded against retained earnings.

In the months up to and including September 2011 DSM bought back 6.8 million outstanding ordinary DSM shares for a cash consideration of €278 million. In the same period 5.7 million ordinary shares were issued in connection with stock dividend, the exercise of options and delivery of performance shares.

Heerlen, 1 November 2011

The Managing Board

Feike Sijbesma, Chairman/CEO
Rolf-Dieter Schwalb, CFO
Stefan Doboczky
Nico Gerardu
Stephan Tanda

Important dates

Annual Report 2011	Wednesday, 29 February 2012
Report for the first quarter 2012	Tuesday, 8 May 2012
Annual General Meeting of Shareholders	Friday, 11 May 2012
Report for the second quarter 2012	Tuesday, 7 August, 2012
Report for the third quarter 2012	Tuesday, 6 November 2012

DSM – Bright Science. Brighter Living.™

Royal DSM N.V. is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, pharmaceuticals, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM's 22,000 employees deliver annual net sales of about €9 billion. The company is listed on NYSE Euronext. More information can be found at www.dsm.com.

For more information

Media
DSM, Corporate Communications
tel.: +31 (45) 5782421
e-mail: media.relations@dsm.com

Investors
DSM, Investor Relations
tel.: +31 (45) 5782864
e-mail: investor.relations@dsm.com

www.dsm.com

Financial Overview Q3 2011

in million of Euros	DSM			Nutrition			Pharma			Performance Materials		
Continuing operations before exceptional	Q3'11	Q3'10	Chg.%	Q3'11	Q3'10	Chg.%	Q3'11	Q3'10	Chg.%	Q3'11	Q3'10	Chg.%
Sales	2,322	2,041	14%	868	751	16%	171	168	2%	711	666	7%
Organic growth			14%			8%			14%			7%
Volume			6%			8%			13%			-4%
Price			8%			0%			1%			11%
Exchange rates			-3%			-2%			-4%			-3%
Other			3%			10%			-8%			3%
EBITDA	339	268 *	26% **	176	167	5%	13	7	+86%	77	72	7%
EBITDA margin (%)	14.6%	13.1%		20.3%	22.2%		7.6%	4.2%		10.8%	10.8%	
DA	108	99		42	34		10	14		30	29	
EBIT	231	169 *	37%	134	133	1%	3	-7		47	43	9%
EBIT margin (%)	9.9%	8.3%		15.4%	17.7%		2%	-		6.6%	6.5%	
EPS (€)	0.94	0.68	38%									

in million of Euros	Polymer Intermediates			Innovation Center			Corporate Activities	
Continuing operations before exceptional	Q3'11	Q3'10	Chg.%	Q3'11	Q3'10	Chg.%	Q3'11	Q3'10
Sales	473	340	39%	15	17	-12%	84	99
Organic growth			45%					
Volume			19%					
Price			26%					
Exchange rates			-6%					
Other								
EBITDA	109	46	+137%	-14	-10		-22	-14
EBITDA margin (%)	23.0%	13.5%						
DA	13	8		2	3		11	11
EBIT	96	38	153%	-16	-13		-33	-25
EBIT margin (%)	20.3%	11.2%						
EPS (€)								

Total DSM before exceptionals			
EBITDA	339	292	16%
Net Profit	159	128	24%

Total DSM incl exceptionals		
Net Profit	171	79
EPS (€)	1.00	0.46

* of which €7 million IFRS pension adjustment

** 30% if IFRS pension adjustment is excluded

Financial Overview YTD 2011

in million of Euros	DSM			Nutrition			Pharma			Performance Materials			Polymer Intermediates			Innovation Center			Corporate Activities	
Continuing operations before exceptional	ytd'11	ytd'10	Chg.%	ytd'11	ytd'10	Chg.%	ytd'11	ytd'10	Chg.%	ytd'11	ytd'10	Chg.%	ytd'11	ytd'10	Chg.%	ytd'11	ytd'10	Chg.%	Q3'11	Q3'10
Sales	6,821	6,049	12%	2,505	2,247	11%	512	549	-7%	2,125	1,867	14%	1,353	1,016	33%	43	35	23%	283	380
Organic growth			13%			4%			-2%			13%			37%					
Volume			6%			6%			-2%			2%			11%					
Price			7%			-2%			0%			11%			26%					
Exchange rates			-2%			-1%			-2%			-1%			-4%					
Other			1%			8%			-3%			2%								
EBITDA	1,003	885 *	13% **	542	521	4%	25	35	-29%	250	227	10%	301	156	93%	-40	-36		-75	-18
EBITDA margin (%)	14.7%	14.6%		21.6%	23.2%		4.9%	6.4%		11.8%	12.2%		22.2%	15.4%						
DA	303	303		114	102		32	43		88	91		29	24		8	8		32	35
EBIT	700	582 *	20%	428	419	2%	-7	-8		162	136	19%	272	132	106%	-48	-44		-107	-53
EBIT margin (%)	10.3%	9.6%		17.1%	18.6%		-	-		7.6%	7.3%		20.1%	13.0%						
EPS	2.82	2.26	25%																	

Total DSM before exceptionals			
EBITDA	1,032	988	4%
Net Profit	497	430	16%

Total DSM incl exceptionals		
Net Profit	729	358
EPS (€)	4.33	2.14

* of which €24 million IFRS pension adjustment

** 16% if IFRS pension adjustment is excluded

DSM BRIGHT SCIENCE. BRIGHTER LIVING.

BRIGHT SCIENCE. BRIGHTER LIVING.™

Address:

DSM Investor Relations
P.O. Box 6500, 6401 JH Heerlen
The Netherlands
Phone: +31 45 5782864
Fax: +31 10 45 90275
Email: investor.relations@dsm.com

www.dsm.com